External Tweet loading...
If nothing shows, it may have been deleted
by @AmerMedicalAssn view original on Twitter
2/ Title IX. This article is missing information about federally mandated reporting processes and protections that legally protect medical students (and all students in the U.S.).
3/Anecdotal beliefs perpetuate harms. A physician expert states “the trainee must amass allies before lodging this complaint…” This is legally incorrect, a single report is enough to trigger Title IX and this reinforces the notion that single reports will not be believed.
4/Confidential advocates. The article briefly mentions the need for multiple reporting mechanisms but does not describe these services. Because of Title IX institutions should include an alternative 24-7 access to confidential advocate services.
5/Non-expert statements. This article relied on non-expert-based opinions on the protections and issues-related gender violence experienced by medical students. Title IX coordinators, trauma experts, and confidential advocates should be included in these discussions.
6/ Cover image. The article thumbnail image depicts a man holding a woman’s hand; based on the content of the article, we assume this is without her consent. If so, this is assault and not harassment, this is misleading and challenges students’ understanding of definitions.
7/The AMA is a powerful leader in medicine that has the potential to support, catalyze, and sustain culture change around #metoo in #meded. We are hopeful that the AMA will take and lead informed action to improve the culture of #meded. #womeninmedicine#sheforshe#heforshe
• • •
Missing some Tweet in this thread? You can try to
force a refresh
3/ Culture. "I still don’t think that the prospect of being sexually assaulted was as bad as watching the next generation of sexual harassers being formed. I think that was the worst part for me." (Nontenure-track faculty) #MeToo#MeTooSTEM#womeinmedicine#MedEd#heforshe
So what are some of the policy barriers and levers…
External Tweet loading...
If nothing shows, it may have been deleted
by @liebschutz view original on Twitter
2/Although CMS requires Part D formularies to include OUD treatment, and mandate Part C Medicare Advantage to cover behav health services related to addiction services, the only FDA approved OAT meeting the Part D definition is bupe/naloxone
3/Further, if bupe/naloxone is administered in an OTP it will not be reimbursed, because an OTP is not a pharmacy, a reimbursement requirement for Part D. Same issue for methadone. Methadone is required to be OTP administered (42 CFR 8.12) it is not a qualified Part D product.